- Home
- YQ vs BOLD Comparison
YQ vs BOLD Comparison
Compare YQ & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | YQ | BOLD |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.7M | 25.7M |
| IPO Year | 2020 | 2024 |
Fundamental Metrics
Financial Performance| Metric | YQ | BOLD |
|---|---|---|
| Price | $1.78 | $1.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 3.7K | ★ 87.3K |
| Earning Date | 03-24-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $0.96 |
| 52 Week High | $6.45 | $1.78 |
Technical Indicators
Market Signals| Indicator | YQ | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 24.52 | 51.27 |
| Support Level | N/A | $1.11 |
| Resistance Level | $2.06 | $1.20 |
| Average True Range (ATR) | 0.19 | 0.05 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 6.38 | 57.69 |
Price Performance
Historical ComparisonAbout YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.